This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International
Delivered as a Hybrid Event
September 27-30, 2022Boston Convention and Exhibition Center

Dan Smith, PhD, FRSB
Executive Director, Global Cell and Gene Therapy Portfolio at Charles River


Following the acquisition of Cobra Biologics/Cognate BioServices by Charles River Laboratories (CRL) in April 2021, Professor Daniel C. Smith was appointed Executive Director, Global Cell & Gene Therapy Portfolio within the CRL Corporate Development & Strategy function. 
 Prior to acquisition, Daniel was the Chief Scientific Officer across the Cognate/Cobra C&GT CDMO portfolio (2020-2021), and Cobra Biologics (2014-2020), driving CDMO innovations and partnerships across plasmid DNA, viral vectors, and latterly, (gene-modified) Cell Therapies, with respect to development and production.  
 Previously he was Knowledge Transfer Manager and Senior Technologist for the BioProcessUK team. Daniel also spent five years (2005-2010) at Cobra in roles including Senior Scientist, QC Team Leader, Head of Process Technology Transfer and Commercial Scientific Development Manager. He has over eight years academic research experience, 30+ research publications to his name and a PhD in Molecular Cell Biology, and a BSc (Hons) in Biochemistry. Daniel holds Honorary Industry Professor positions at both the University of Kent, UK and at the University of Warwick, UK. 

Agenda Sessions

  • Implementing a sustainable manufacturing strategy to accelerate time to clinic and cure